PMID- 32245325
OWN - NLM
STAT- MEDLINE
DCOM- 20201201
LR  - 20201201
IS  - 1735-5249 (Electronic)
IS  - 1735-1502 (Linking)
VI  - 19
IP  - 1
DP  - 2020 Feb 1
TI  - Inflammatory and T Helper 17/ Regulatory T Cells Related Cytokines Balance in 
      Cutaneous Lupus Erythematosus (CLE).
PG  - 9-17
LID - 10.18502/ijaai.v19i1.2411 [doi]
AB  - The cutaneous lupus erythematosus (CLE) is a common manifestation among systemic 
      lupus erythematosus (SLE) patients. Malar rash and discoid lupus (DLE) are in the 
      category of acute and chronic CLE, respectively. The pathogenesis of CLE is 
      multifactorial, and cytokine imbalances contribute to immune dysfunction and the 
      induction of organ damage. Many aspects of cytokine dysregulation are still 
      unclear in SLE and in particular CLE. Therefore, we concurrently measured the 
      inflammatory [Tumor necrosis factor-alpha (TNF-alpha) and Interleukin (IL)-6)], T 
      helper (Th)-17 (IL-17 and IL-23) and regulatory T cells [Transforming growth 
      factor-beta (TGFbeta) and IL-10)]-related cytokines in patients with CLE (patients 
      with malar rash and/or DLE) and compared them with SLE patients and healthy 
      individuals (n=25 in each group, a total of 75 patients). The serum levels of 
      cytokines were assessed by Enzyme-Linked Immunosorbent Assay (ELISA) method. IL-6 
      cytokine was significantly higher in SLE, DLE, and malar rash patients compared 
      to those in healthy controls (p=0.025) and in patients with arthralgia (p=0.038), 
      and gastrointestinal involvement (p=0.048). IL-17 was significantly higher in 
      malar rash patients compared to normal individuals (p=0.023), SLE (p=0.008) and 
      DLE patients (p=0.019) and in patients with oropharyngeal ulcer (p=0.05) but, 
      IL-23 was significantly higher only in DLE patients than healthy controls 
      (p=0.019). In conclusion, inflammatory cytokines such as IL-6 involved in 
      inflammation and differentiation of Th17 cells are probably responsible in part 
      for Th17 activity in CLE. IL-17, IL-23, and IL-6/IL-6R (IL-6 receptor) inhibitors 
      may be good treatments for CLE patients. So targeting these cytokines activity 
      pathways can improve the CLE treatment strategy and may open a novel guideline 
      for SLE and CLE treatment.
FAU - Yazdani, Mohammad-Reza
AU  - Yazdani MR
AD  - Autoimmune Diseases Research Center, Shiraz University of Medical Sciences, 
      Shiraz, Iran. yazdanimr@yahoo.com.
FAU - Aflaki, Elham
AU  - Aflaki E
AD  - Autoimmune Diseases Research Center, Shiraz University of Medical Sciences, 
      Shiraz, Iran AND Department of Rheumatology, Shiraz University of Medical 
      Sciences, Shiraz, Iran. aflakie@gmail.com.
FAU - Gholijani, Nasser
AU  - Gholijani N
AD  - Autoimmune Diseases Research Center, Shiraz University of Medical Sciences, 
      Shiraz, Iran. gholijani@yahoo.com.
LA  - eng
PT  - Journal Article
DEP - 20200201
PL  - Iran
TA  - Iran J Allergy Asthma Immunol
JT  - Iranian journal of allergy, asthma, and immunology
JID - 101146178
RN  - 0 (Cytokines)
SB  - IM
MH  - Adult
MH  - Case-Control Studies
MH  - Cytokines/blood/*immunology
MH  - Female
MH  - Humans
MH  - Inflammation/immunology
MH  - Lupus Erythematosus, Cutaneous/*immunology
MH  - Male
MH  - T-Lymphocytes, Regulatory/*immunology
MH  - Th17 Cells/*immunology
OTO - NOTNLM
OT  - Cutaneous lupus erythematosus
OT  - Inflammatory cytokines
OT  - Regulatory T cells
OT  - T helper 17
EDAT- 2020/04/05 06:00
MHDA- 2020/12/02 06:00
CRDT- 2020/04/05 06:00
PHST- 2019/05/22 00:00 [received]
PHST- 2019/08/26 00:00 [accepted]
PHST- 2020/04/05 06:00 [entrez]
PHST- 2020/04/05 06:00 [pubmed]
PHST- 2020/12/02 06:00 [medline]
AID - 10.18502/ijaai.v19i1.2411 [doi]
PST - epublish
SO  - Iran J Allergy Asthma Immunol. 2020 Feb 1;19(1):9-17. doi: 
      10.18502/ijaai.v19i1.2411.